Keylicon Biosciences Inc.
Brookline, MA
- UEI
- UXSKUT48A7W3
- CAGE
- 9XGR7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 189 Tappan St, Brookline, MA 02445, USA
- Website
- keylicon.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Extended in situ production of glucocerebrosidase (gcase) for the treatment of gaucher disease - project… | National Institute of Diabetes and Digestive and Kidney Diseases | $400,000 | |
| Low dose multivalent influenza vaccine via modified self-amplifying RNA - project summary/abstract seasonal influenza… | National Institute of Allergy and Infectious Diseases | $314,363 | |
| Multivalent vaccine against lyme disease via modified self-amplifying RNA - project summary/abstract lyme disease, the… | National Institute of Allergy and Infectious Diseases | $314,363 |
Quick answers
What is Keylicon Biosciences Inc.'s UEI?
Keylicon Biosciences Inc.'s Unique Entity ID (UEI) in SAM.gov is UXSKUT48A7W3.
What is Keylicon Biosciences Inc.'s CAGE code?
Keylicon Biosciences Inc.'s CAGE code is 9XGR7.
What is Keylicon Biosciences Inc.'s primary NAICS code?
Keylicon Biosciences Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Keylicon Biosciences Inc. located?
Keylicon Biosciences Inc.'s physical address in SAM.gov is 189 Tappan St, Brookline, MA 02445, USA.
Is Keylicon Biosciences Inc. registered in SAM.gov?
Yes. Keylicon Biosciences Inc.'s SAM.gov registration is active through January 22, 2027.
What is Keylicon Biosciences Inc.'s most recent federal award?
Keylicon Biosciences Inc.'s most recent federal grant award is Extended in situ production of glucocerebrosidase (gcase) for the treatment of gaucher disease - project… (R43DK146746), from National Institute of Diabetes and Digestive and Kidney Diseases, on September 1, 2026.
On GovTribe
See Keylicon Biosciences Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors